Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies
Ananta Swargiary
doi:10.21203/rs.3.rs-73308/v1
Purpose: COVID-19, caused by SARS-CoV2 virus is a contagious disease affecting millions of lives throughout the globe. Currently, there are no clinically approved drugs for SARS-CoV2 although some drugs are undergoing clinical trials. The present study investigates the binding property of ivermectin on four important drug targets, spike protein, RNA-dependent RNA polymerase, 3-chymotrypsin-and papainlike proteases of SARS-CoV2. Methods: The 3D structure of ivermectin along with known antiviral drug lopinavir, simeprevir and four nucleotides ATP, GTP, CTP, and UTP were
Ethics approval: NA Consent to participate: NA Consent for publication: Author gives the consent to publish the manuscript
References
Anand, Ziebuhr, Wadhwani, Mesters, Hilgenfeld et al., Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase, J Biomol Struct Dyn. Doi,
doi:10.1126/science.1085658
Benvenuto, Giovanetti, Ciccozzi, Spoto, Angeletti et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res,
doi:10.1002/jmv.25688
Canga, Prieto, Liebana, Martinez, Vega et al., The Pharmacokinetics and Interactions of Ivermectin in Humans -A Mini-review, AAPS J,
doi:10.1208/s12248-007-9000-9
Chen, Yiu, Wong, Prediction of the SARSCoV-2 (2019-nCoV) 3C-like protease (3CL (pro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates, F1000Research,
doi:10.12688/f1000research.22457.1
Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Res,
doi:.org/10.1016/j.antiviral.2018.09.010
Patrì, Fabbrocini, Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?, J Am Acad Dermatol,
doi:10.1016/j.jaad.2020.04.017
Sharun, Dhama, Patel, Pathak, Tiwari et al., Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Ann Clin Microbiol Antimicrob,
doi:10.1186/s12941-020-00368-w
Touret, Gilles, Barral, Nougairede, Helden et al., In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Sci Rep,
doi:10.1038/s41598-020-70143-6
Trott, Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, e cient optimization and multithreading, J Comput Chem,
doi:10.1002/jcc.21334
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0
Xu, Liu, Weiss, Sg, Ding, Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design, Nucleic Acids Res,
doi:10.1093/nar/gkg916
Yin, Mao, Luan, Shen, Shen et al., Structural basis for inhibition of the RNAdependent RNA polymerase from SARS-CoV-2 by remdesivir, Science,
doi:10.1126/science.abc1560
Zhou, Fang, Yang, Xu, Lv et al., Identi cation of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach, The FASEB Journal,
doi:10.1096/fj.201901624RR